technetium-tc-99m-exametazime and Parkinson-Disease

technetium-tc-99m-exametazime has been researched along with Parkinson-Disease* in 31 studies

Reviews

2 review(s) available for technetium-tc-99m-exametazime and Parkinson-Disease

ArticleYear
Significance of non-presynaptic SPECT tracer methods in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18 Suppl 7

    Tropane-related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D(2) receptors and HMPAO uptake is a measure of cerebral tissue perfusion.

    Topics: Benzamides; Brain; Corpus Striatum; Diagnosis, Differential; Humans; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Receptors, Presynaptic; Regional Blood Flow; Sensitivity and Specificity; Technetium Tc 99m Exametazime; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon

2003
Brain SPECT imaging of neuropsychiatric disorders.
    European journal of radiology, 1996, Volume: 21, Issue:3

    Brain imaging has become an integral part of the evaluation of neurological and psychiatric disorders. Functional imaging techniques, SPECT and PET, together with structural modalities, CT and MRI, are widely employed. Functional imaging studies are routinely used in the diagnostic workup of patients with well-characterized neurological disorders, such as epilepsy and brain tumors, and have a growing role in research on psychiatric disorders without known mechanisms such as depression and schizophrenia. Furthermore, many well-defined neurological disorders manifest prominent psychiatric symptomatology which may pose difficulties in differential diagnosis. This review addresses the current knowledge of SPECT findings in patients who present with psychiatric phenomena, associated with disorders at the interface of neurology and psychiatry.

    Topics: Alzheimer Disease; Brain; Brain Damage, Chronic; Brain Diseases; Brain Injuries; Brain Neoplasms; Dementia; Diagnosis, Differential; Epilepsy, Temporal Lobe; Humans; Huntington Disease; Neurocognitive Disorders; Organotechnetium Compounds; Oximes; Parkinson Disease; Regional Blood Flow; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1996

Trials

1 trial(s) available for technetium-tc-99m-exametazime and Parkinson-Disease

ArticleYear
[Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Nuklearmedizin. Nuclear medicine, 1994, Volume: 33, Issue:5

    The aim of this SPECT study was to determine whether there is a correlation between rCBF (99mTc-HMPAO) and D2 receptor binding (123I-IBZM) in disorders of the extrapyramidal system and in which situation the 99mTc-HMPAO scan could predict the outcome of the 123I-IBZM study. 13 patients with Parkinson's syndrome and 13 patients with hyperkinetic extrapyramidal disorders were studied. In all patients the two SPECT studies were performed within 2-7 days. ROIs were placed over the basal ganglia (BG), the frontal cortex (FC) and the cerebellum (CE). The ratios BG/FC and BG/CE were calculated. In both groups the scatter was lower when the frontal cortex was used as reference region. Among the patients with hyperkinetic extrapyramidal disorders the two patients with Huntington's chorea had lower rCBF and D2 receptor binding compared to other hyperkinetic extrapyramidal disorders. There was no correlation between D2 receptor binding and rCBF in the basal ganglia. The 99mTc-HMPAO studies did not provide clinically useful information, except in Huntington's chorea.

    Topics: Adult; Aged; Basal Ganglia; Basal Ganglia Diseases; Benzamides; Brain; Cerebellum; Cerebrovascular Circulation; Dopamine Antagonists; Frontal Lobe; Humans; Huntington Disease; Iodine Radioisotopes; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Parkinson Disease, Secondary; Pyrrolidines; Receptors, Dopamine D2; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1994

Other Studies

28 other study(ies) available for technetium-tc-99m-exametazime and Parkinson-Disease

ArticleYear
Correlated regions of cerebral blood flow with clinical parameters in Parkinson's disease; comparison using 'Anatomy' and 'Talairach Daemon' software.
    Annals of nuclear medicine, 2012, Volume: 26, Issue:2

    We assign the anatomical names of functional activation regions in the brain, based on the probabilistic cyto-architectonic atlas by Anatomy 1.7 from an analysis of correlations between regional cerebral blood flow (rCBF) and clinical parameters of the non-demented Parkinson's disease (PD) patients by SPM8. We evaluated Anatomy 1.7 of SPM toolbox compared to 'Talairach Daemon' (TD) Client 2.4.2 software.. One hundred and thirty-six patients (mean age 60.0 ± 9.09 years; 73 women and 63 men) with non-demented PD were selected. Tc-99m-HMPAO brain single-photon emission computed tomography (SPECT) scans were performed on the patients using a two-head gamma-camera. We analyzed the brain image of PD patients by SPM8 and found the anatomical names of correlated regions of rCBF perfusion with the clinical parameters using TD Client 2.4.2 and Anatomy 1.7. The SPM8 provided a correlation coefficient between clinical parameters and cerebral hypoperfusion by a simple regression method. To the clinical parameters were added age, duration of disease, education period, Hoehn and Yahr (H&Y) stage and Korean mini-mental state examination (K-MMSE) score.. Age was correlated with cerebral perfusion in the Brodmann area (BA) 6 and BA 3b assigned by Anatomy 1.7 and BA 6 and pyramis in gray matter by TD Client 2.4.2 with p < 0.001 uncorrected. Also, assigned significant correlated regions were found in the left and right lobules VI (Hem) with duration of disease, in left and right lobules VIIa crus I (Hem) with education, in left insula (Ig2), left and right lobules VI (Hem) with H&Y, and in BA 4a and 6 with K-MMSE score with p < 0.05 uncorrected by Anatomy 1.7, respectively. Most areas of correlation were overlapped by two different anatomical labeling methods, but some correlation areas were found with different names.. Age was the most significantly correlated clinical parameter with rCBF. TD Client found the exact anatomical name by the peak intensity position of the cluster while Anatomy 1.7 of SPM8 toolbox, using the cyto-architectonic probability maps, assigned the anatomical name by percentage value of the probability.

    Topics: Aged; Brain; Cerebrovascular Circulation; Female; Humans; Male; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Software; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

2012
[123I]-FP-CIT and [99mTc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia-parkinsonism.
    Journal of the neurological sciences, 2008, Oct-15, Volume: 273, Issue:1-2

    Rapid-onset dystonia-parkinsonism (RDP) is a rare, autosomal-dominantly inherited syndrome characterized by abrupt onset, over hours to days, of dystonic and parkinsonian symptoms. To date, RDP has been described in a small number of families, and in only four sporadic cases.. We here report a new sporadic case of RDP who has a novel de novo mutation in the ATP1A3 gene. Striatal dopamine transporters have been assessed quantitatively using [123I]-FP-CIT SPECT. A volume of interest (VOI) was drawn within the occipital cortex to obtain non-specific activity and specific to non-specific binding ratios (BR) were calculated. A single template of predefined VOI 3D-drawn on right and left caudate nucleus and putamen was applied to the spatially normalized BR images. BR values were compared to those obtained from an age-matched control group and from a group of patients suffering from Parkinson's disease (Hoehn and Yahr score 2 or 3). A [99mTc]-HMPAO cerebral blood flow study was also performed.. In the control group, BR values (mean+/-Standard Deviation) were 3.5+/-0.4 for the left striatum and 3.3+/-0.3 for the right one. RDP patient's values were 3 and 2.7, respectively. In the Parkinson group, values were 1.6+/-0.3 and 1.7+/-0.4, respectively. [99mTc]-HMPAO scan showed homogeneous cortical and sub-cortical perfusion.. Quantification of striatal [123I]-FP-CIT uptake in a new sporadic case of RDP with a novel mutation in the ATP1A3 gene showed values just within the range of normality. [99mTc]-HMPAO scan was normal.

    Topics: Adult; Dystonia; Humans; Iodine Radioisotopes; Male; Mutation; Parkinson Disease; Sodium-Potassium-Exchanging ATPase; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2008
Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy.
    Annals of nuclear medicine, 2008, Volume: 22, Issue:7

    (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is a useful tool for differentiating idiopathic Parkinson's disease (PD) from parkinsonism (PS) caused by other disorders. However, cardiac MIBG uptake is affected by various causes. Alternatively, hypoperfusion in the occipital lobe of PD is reported recently.. The objective is to clarify the correlation between regional cerebral blood flow (rCBF) alteration and cardiac MIBG uptake in PD. In addition, we examined whether additional brain perfusion analysis improved the differential diagnostic ability for PD from PS when compared with MIBG scintigraphy alone.. Forty-nine patients with PD (27 mild groups: Hoehn and Yahr stages I, II; 22 severe groups: Hoehn and Yahr stages III, IV) and 28 patients with PS participated. We compared absolute rCBF values between PD and PS. In addition, we determined correlation between MIBG parameters and each rCBF value. Finally, we compared the diagnostic ability for the differentiation of PD from PS between two diagnostic criteria, each MIBG index abnormality alone [heart-to-mediastinum ratio, H/M (E) < 1.9, H/E (D) < 1.7, washout rate > 40%] and each MIBG index abnormality or occipital lobe hypoperfusion (<36 ml/100 g per min).. Absolute rCBF value of occipital lobe was significantly lower in severe PD as compared with PS or mild PD. In the correlation analysis, rCBF of occipital lobe correlated positively with MIBG parameters (H/M). Regarding the diagnostic ability, sensitivity improved by accounting for occipital hypoperfusion as compared with MIBG indices alone. In contrast, neither specificity nor accuracy improved by adding occipital lobe analysis.. MIBG parameters (H/M) correlated positively with occipital hypoperfusion in PD. In the differential diagnosis between PD and PS, although its usefulness might be limited, analysis of rCBF in the occipital lobe added to (123)I-MIBG myocardial imaging can be recommended.

    Topics: 3-Iodobenzylguanidine; Aged; Cerebrovascular Circulation; Cross-Sectional Studies; Diagnosis, Differential; Female; Heart; Humans; Lewy Body Disease; Male; Middle Aged; Occipital Lobe; Parkinson Disease; Parkinson Disease, Secondary; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

2008
Regional CBF changes in Parkinson's disease: the importance of functional neuroimaging analyses.
    European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:9

    Topics: Aged; Brain; Cerebrovascular Circulation; Diagnostic Imaging; Humans; Models, Statistical; Parkinson Disease; Perfusion; Radiopharmaceuticals; Reproducibility of Results; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2007
Corticobasal degeneration and Parkinson's disease assessed by HmPaO SPECT: the utility of factorial discriminant analysis.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:11

    The diagnosis of corticobasal degeneration (CBD) is difficult despite the existence of some typical clinical features. Single photon emission computerized tomography (SPECT) in CBD presents an original pattern (with asymmetric hypoperfusion in pre- and retrorolandic regions) that could facilitate the differential diagnosis of CBD relative to the other degenerative parkinsonian syndromes. The objective of our study was to compare the regional cerebral blood flow measurements studied by SPECT in both CBD and Parkinson's disease (PD) using a multivariate procedure. Twenty-one patients with probable CBD and 20 patients with probable PD underwent brain (99m)Tc HmPaO SPECT. We used factorial discriminant analysis (FDA) to study the relative fixation of 26 regions of interest (ROIs) drawn on two transverse slices, together with the asymmetry indexes of 13 pairs of ROIs. FDA performed using the full set of parameters classified all the patients correctly. In order to classify the patients more easily, a predictive score using a selection of parameters was established. The most discriminating ROIs were the temporoinsular, temporoparietal, and frontal medial regions. We believe that this semiautomatic classification may be a precious tool for reinforcing the current clinical differential diagnosis of CBD and PD.

    Topics: Aged; Basal Ganglia Diseases; Cerebrovascular Circulation; Discriminant Analysis; Female; Humans; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Statistics, Nonparametric; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

2005
Absolute activity quantitation in simultaneous 123I/99mTc brain SPECT.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, Volume: 42, Issue:2

    Dual-isotope imaging can allow simultaneous assessment of brain perfusion using a 99mTc-labeled tracer and neurotransmission using an 123I-labeled tracer. However, the images are affected by scatter, cross talk, attenuation, distance-dependent collimator response (DCR), and partial-volume effect. We determined the accuracy and precision of activity quantitation in simulated normal and pathologic studies of simultaneous 123I/99mTc brain SPECT when compensating for all degrading phenomena.. Monte Carlo simulations were performed using the Zubal brain phantom. Contamination caused by high-energy 123I decay photons was incorporated. Twenty-four 99mTc and 123I activity distributions were simulated on the basis of normal and pathologic patient activity distributions. Cross talk and scatter were corrected using a new method based on a multilayer perceptron artificial neural network (ANN), as well as by the asymmetric window (AW) approach; for comparison, unscattered (U) photons of 99mTc and 123I were recorded. Nonuniform attenuation and DCR were modeled in an iterative ordered-subset expectation maximization (OSEM) algorithm. Mean percentage biases and SDs over the 12 normal and 12 pathologic simulated studies were computed for each structure with respect to the known activity distributions.. For 123I, AW + OSEM yielded a bias of 7% in the cerebellum, 21% in the frontal cortex, and 36% in the corpus callosum in the simulated normal population. The bias was increased significantly in the striata of simulated pathologic studies (P < 0.05). The bias associated with ANN was significantly lower (<9% in these brain structures, P < 0.05). For 99mTc with AW + OSEM, the bias was 60% in the corpus callosum, 36% in the striata, and 18%-22% in the cortical lobes in the simulated normal population. This bias was <11% in all brain structures with ANN. In the simulated pathologic population, the bias associated with AW increased significantly in the cortical lobes to 55% (P < 0.05), although it did not change significantly with ANN.. The accuracy and variability over simulated normal and pathologic studies of both 99mTc and 123I activity estimates were very close with ANN to those obtained with U + OSEM. ANN + OSEM is a promising approach for absolute activity quantitation in simultaneous 99mTc/123I SPECT.

    Topics: Alzheimer Disease; Benzamides; Brain; Cerebellum; Cerebral Cortex; Cerebrovascular Circulation; Corpus Callosum; Humans; Iodine Radioisotopes; Monte Carlo Method; Neural Networks, Computer; Parkinson Disease; Phantoms, Imaging; Putamen; Pyrrolidines; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

2001
Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1999, Volume: 40, Issue:6

    The aim of this study was to compare the regional cerebral blood flow measurements studied by SPECT in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) to determine the contribution of SPECT to the differential diagnosis of these two diseases.. SPECT analysis with 99mTc-hexamethyl propyleneamine oxime (HMPAO) was performed in 20 patients with probable DLB, 20 patients with probable AD and 20 patients with idiopathic Parkinson's disease (IPD). Ten pairs of regions of interest were analyzed. Tracer uptake was expressed as a corticocerebellar activity ratio.. Compared with IPD, in the DLB group there was a global decrease of HMPAO uptake in cortical regions of interest except in the posterior frontal and occipital regions; in the AD group there was limited left temporal and parietal hypoperfusion. In the DLB group, frontal HMPAO uptake was significantly lower than in the AD group. Two predictive scores were established by a factorial discriminant analysis from six left cortical indices (medial frontal, lateral frontal, posterior frontal, temporoparietal, parietal and parietooccipital) and the Mini-Mental State Examination, which correctly classified 53 of 60 patients (88%) (DLB, 18 of 20; AD, 16 of 20; IPD, 19 of 20).. These findings indicate the presence of diffuse cortical abnormalities in DLB and suggest that SPECT may be useful in discriminating in vivo DLB from AD, revealing mainly frontal hypoperfusion in the former group. We estimate that SPECT study increases the possibility of separating DLB and AD because both disorders share different patterns of cerebral blood flow abnormality.

    Topics: Aged; Alzheimer Disease; Brain; Cerebral Cortex; Cerebrovascular Circulation; Data Interpretation, Statistical; Diagnosis, Differential; Humans; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1999
A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia?
    Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 64, Issue:3

    To provide the clinician with a guide to the clinical utility of 99mTc-HMPAO single photon emission computed tomography (SPECT) and to the interpretation of specific test results in the differential diagnosis of dementia.. Three hundred and sixty three patients with dementia were studied prospectively for a median three (range 1-6) years and classified into disease groups on the basis of established clinical criteria. The degree to which different patterns of cerebral blood flow (CBF) abnormality found on 99mTc-HMPAO SPECT imaging at the time of initial patient presentation modified clinical diagnoses was determined by calculating the likelihood ratios for pairwise disease group comparisons. The optimal clinical usage of 99mTc-HMPAO SPECT was determined by calculating the percentage of significant test results for each pairwise disease group comparison.. Bilateral posterior CBF abnormality was found to significantly increase the odds of a patient having Alzheimer's disease as opposed to vascular dementia or frontotemporal dementia. Bilateral anterior CBF abnormality significantly increased the odds of a patient having frontotemporal dementia as opposed to Alzheimer's disease, vascular dementia, or Lewy body disease. "Patchy" CBF changes significantly increased the odds of a patient having vascular dementia as opposed to Alzheimer's disease. Unilateral anterior, unilateral anterior plus unilateral posterior, and generalised CBF abnormality failed to contribute to the differentiation of any of these forms of dementia.. 99mTc-HMPAO SPECT was found to be most useful in distinguishing Alzheimer's disease from vascular dementia and fronto temporal dementia, and least useful in differentiating between Alzheimer's disease and Lewy body disease, and between vascular dementia, frontotemporal dementia, and progressive aphasia. It is suggested that CBF SPECT should be used selectively and as an adjunct to clinical evaluation and CT.

    Topics: Aged; Alzheimer Disease; Aphasia, Primary Progressive; Dementia; Dementia, Vascular; Diagnosis, Differential; Female; Humans; Likelihood Functions; Male; Middle Aged; Odds Ratio; Parkinson Disease; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1998
Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.
    European journal of nuclear medicine, 1997, Volume: 24, Issue:3

    Dementia of the Alzheimer-type (DAT) is characterized by progressive cognitive decline, variably combined with frontal lobe release signs, parkinsonian symptoms and myoclonus. The features of diffuse Lewy body disease (DLBD), the second most common cause of degenerative dementia, include progressive cognitive deterioration, often associated with levodopa-responsive parkinsonism, fluctuations of cognitive and motor functions, psychotic symptoms (visual and auditory hallucinations, depression), hypersensitivity to neuroleptics and orthostatic hypotension. A recent report suggests that positron emission tomography studies in patients with degenerative dementia may be useful in the differential diagnosis of DAT and DLBD. However, the diagnostic role of single-photon emission tomography (SPET) studies remains to be established. The aim of this study was therefore to evaluate regional cerebral perfusion [with either technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO) or 99mTc-ethyl cysteinate dimer (99mTc-ECD) SPET] and striatal dopamine transporter density [using iodine-123 2 beta-carboxymethoxy-3 beta-[4-iodophenyl]tropane (123I-beta-CIT) SPET] in patients with DAT and DLBD. Six patients with probable DAT and seven patients with probable DLBD were studied. Blinded qualitative assessment by four independent raters of 99mTc-HMPAO or 99mTc-ECD SPET studies revealed bilateral temporal and/or parietal hypoperfusion in all DAT patients. There was additional frontal hypoperfusion in two patients and occipital hypoperfusion in one patient. In the DLBD group, regional cerebral perfusion had a different pattern. In addition to temporoparietal hypoperfusion there was occipital hypoperfusion resembling a horseshoe defect in six of seven patients. In the DAT group, the mean 3-h striatal/cerebellar ratio of 123I-beta-CIT binding was 2.5 +/- 0.4, with an increase to 5.5 +/- 1.1 18 h after tracer injection. In comparison, in the DLBD patients the mean 3-h striatal/cerebellar ratio of 123I-beta-CIT binding was significantly reduced to 1.7 +/- 0.3, with a modest increase to 2.1 +/- 0.4 18 h after tracer injection (P < 0.05, Scheffe test, ANOVA). These results suggest that 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT SPET may contribute to the differential diagnosis between DAT and DLBD, showing different perfusion patterns and more severe impairment of dopamine transporter function in DLBD than in DAT.

    Topics: Aged; Alzheimer Disease; Brain; Carrier Proteins; Case-Control Studies; Cocaine; Cysteine; Dementia; Diagnosis, Differential; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Organotechnetium Compounds; Oximes; Parkinson Disease; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1997
A 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease.
    Journal of neurology, 1997, Volume: 244, Issue:6

    The purpose of this study was to investigate patterns of 99mTc-HMPAO single-photon emission computed tomography (SPECT) abnormality in Lewy body disease (LBD) and to compare findings with those encountered in Alzheimer's disease (AD). The study group comprised 20 consecutive patient referrals fulfilling clinical criteria for LBD. All patients had fluctuating cognitive impairment and 'subcortical' dysfunction with or without perceptuospatial and/or linguistic impairment. Six patients had asymmetrical signs of parkinsonism (three left-sided and three right-sided), and 14 patients had symmetrical features of extrapyramidal involvement. 99mTc-HMPAO SPECT imaging was performed on LBD patients and findings compared with those of 57 patients with 'probable' AD and 11 normal age-matched controls. Within the LBD and AD groups, patterns of cortical and subcortical blood-flow abnormality were compared with patterns of cognitive and neurological breakdown. LBD was associated with bilateral posterior cortical blood flow abnormality, a pattern strikingly similar to that found in AD. Within the LBD group, cortical blood-flow abnormality was found to reflect patterns of neurological dysfunction (parkinsonism) indicative of subcortical involvement. In contrast, cortical blood-flow changes did not reflect patterns of neuropsychological impairment suggestive of cortical dysfunction. Within the AD group, cortical blood-flow changes were mirrored by the pattern of neuropsychological impairment. Findings support the notion that cortical blood-flow abnormality in LBD might reflect a combination of direct cortical pathology and cortical deafferentation secondary to subcortical Lewy body pathology. It would appear that 99mTc-HMPAO SPECT imaging is of limited value in the clinical differentiation of LBD and AD.

    Topics: Aged; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Female; Humans; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1997
Tomographic measurements of regional cerebral blood flow in progressive supranuclear palsy and Parkinson's disease.
    Acta neurologica Scandinavica, 1995, Volume: 92, Issue:3

    Intellectual changes observed in progressive supranuclear palsy (PSP) are sometimes seen with lesser intensity in Parkinson's disease (PD). Cognitive impairment of PSP has been attributed to a frontal lobe dysfunction explaining the frontal cortex hypometabolism detected by PET. To establish whether this frontal hypometabolism is more pronounced in PSP than in PD, we compared frontal and temporo-parietal cerebral blood flow (CBF) indexes studied by SPECT using Tc99m HmPAO in 18 PSP, 18 PD and 8 control subjects. For each patient neuropsychological performances were also assessed. A significant left frontal hypoperfusion was observed in PSP (mean index value: 0.78 +/- 0.03, p < 0.01) and PD (0.78 +/- 0.04, p < 0.05) as compared to controls (0.84 +/- 0.03), whereas there was no difference between PSP and PD. No correlation was discovered between neuropsychological performances and frontal cortical index changes. This frontal uptake reduction of Tc99m HmPAO in PSP and PD could result from a disconnection phenomenon secondary to subcortical lesions. In both groups mean frontal indexes showed only a left frontal hypoperfusion suggesting that subcortical structures might be asymmetrically involved in early stages of the diseases. The lack of difference for indexe values between PSP and PD might be explained by the difference between the mean disease duration: 4.3 years for the PSP and 7.8 years for the PD. It might also suggest that frontal CBF reduction exists in the same proportions in PD and PSP, but at a later stage in the former case.

    Topics: Aged; Aged, 80 and over; Blood Flow Velocity; Blood Glucose; Brain Mapping; Cerebral Cortex; Dominance, Cerebral; Energy Metabolism; Female; Frontal Lobe; Humans; Male; Middle Aged; Neuropsychological Tests; Organotechnetium Compounds; Oximes; Parkinson Disease; Reference Values; Regional Blood Flow; Supranuclear Palsy, Progressive; Technetium Tc 99m Exametazime; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon

1995
Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1995, Volume: 36, Issue:7

    We used equilibrium analysis of SPECT data from patients with asymmetric Parkinson's disease to determine if lateralized differences in the striatal uptake of [123I]IBZM correlate with asymmetry in clinical findings and, by inference, with lateralized differences in the concentration of extracellular dopamine.. Twelve patients with asymmetric clinical signs of idiopathic Parkinson's disease were injected with a bolus of [123I]IBZM, and multiple SPECT scans recorded the time course of radioligand uptake. The time integral method was used to estimate peak specific binding, so that a ratio of specific-to-nonspecific binding in the left and right striatum of each subject at equilibrium could be determined. Nine patients also had 99mTc-HMPAO SPECT scans which were examined for evidence of blood flow asymmetries.. Paired t-tests comparing [123I]IBZM uptake revealed significantly greater (mean = 7.3%) availability of dopamine-D2 receptors in the basal ganglia contralateral to maximal clinical signs. Differences in receptor availability correlated significantly with differences in every measure of the clinical assessment. No significant differences in regional cerebral blood flow between the two sides were observed with 99mTc-HMPAO.. These results demonstrate the ability of [123I]IBZM SPECT to reveal clinically meaningful variations in striatal dopamine receptor availability in patients with asymmetric Parkinson's disease. The equilibrium analysis technique used to determine these findings is a simple and robust method of measuring relative receptor availability and may be useful in studying other illnesses where dysfunction of dopaminergic neurotransmission is suspected.

    Topics: Adult; Aged; Basal Ganglia; Benzamides; Cerebrovascular Circulation; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1995
Failure of dopamine metabolism: borderlines of parkinsonism and dementia.
    Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma, 1995, Volume: 66, Issue:3-4

    Dementia in parkinsonian patients is estimated to 10-40%. Several factors may take part in the development of cognitive impairment: i/ defective function of subcortico-cortical pathways including the mesocorticolimbic dopamine deficiency with cell loss in medial substantia nigra, the degeneration of noradrenergic, serotonergic and cholinergic systems ii/ cortical and limbic Alzheimer pathology iii/ cortical Lewy bodies iv/ vascular alterations. Using HMPAO SPECT we distinguished three main types of hypoperfusion in Parkinson patients with dementia: i/ predominantly frontal lobe type ii/ posterior ("Alzheimer-like") type iii/ multiple small vascular defects. Neuropsychological investigation was based on the use of MMSE, word pair, digit span, verbal fluency, Lurija's tapping tests. In addition CURS and Hachinski's score were also applied. Selegiline (JumexR) therapy was introduced and the patients were followed for at least 60 days. Selegiline improved significantly the MMSE values and verbal fluency in the "frontal lobe" type further the memory functions in "Alzheimer-like" patients. The mechanism is still not clarified, the increased dopaminergic tone should be taken into account.

    Topics: Antiparkinson Agents; Brain; Chronic Disease; Dementia; Dopamine; Humans; Neuropsychological Tests; Organotechnetium Compounds; Oximes; Parkinson Disease; Selegiline; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1995
Cerebral blood flow in corticobasal degeneration.
    Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:6

    Topics: Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Diagnosis, Differential; Frontal Lobe; Humans; Image Processing, Computer-Assisted; Nerve Degeneration; Organotechnetium Compounds; Oximes; Parietal Lobe; Parkinson Disease; Regional Blood Flow; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1995
HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.
    Journal of neurology, neurosurgery, and psychiatry, 1994, Volume: 57, Issue:2

    Regional cerebral perfusion was evaluated by SPECT with technetium 99m hexamethylpropyleneamine oxime (99mTc HMPAO) as a tracer in 21 patients presenting with Parkinson's disease and in 11 normal controls. In the parkinsonian patients, scans were performed both off treatment, and after levodopa, and clinical dopaminergic responsiveness was evaluated. Uptake of HMPAO by the basal ganglia was significantly decreased in the parkinsonian subjects, compared with normal controls. This reduction was seen in both responders (n = 14) and non-responders (n = 7) to dopaminergic treatment. Uptake of HMPAO by the basal ganglia rose after treatment with levodopa, but the change was similar in both responders and non-responders. By contrast a striking difference in cortical HMPAO uptake was found between responders and non-responders, with significantly lower uptake in the medial temporal and posterior parietal cortex in the non-responders. This reduction was symmetrical. Basal ganglia perfusion assessed by this technique is unlikely to be of use in the diagnosis of Parkinson's disease that is responsive to dopaminergic treatment. The presence of extensive cortical involvement on a baseline scan correlates with a lack of dopaminergic responsiveness, however, and this may be useful diagnostically.

    Topics: Aged; Brain; Female; Humans; Levodopa; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1994
Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
    European neurology, 1993, Volume: 33, Issue:2

    Single photon emission tomography (SPET) with the novel ligand [123I]-IBZM was used to image central dopamine D2 receptors in Parkinson's disease (PD) patients. The aim was to assess basal ganglia (BG) receptor densities in relation to the response to L-dopa therapy. To better characterize the clinical potential of [123I]-IBZM SPET, each patient underwent a second study with the regional perfusion tracer [99mTc]-HM-PAO. Tracer activity ratios were calculated for caudate and putamen with mean activity over the cerebellar hemispheres as internal standard. In PD patients we found a significant decline of mean caudate [123I]-IBZM activity, as compared with age-matched control subjects. However, when patients were grouped according to their therapeutic behavior, the [123I]-IBZM uptake in BG ganglia regions of the PD patient group with a poor and fluctuating response to L-dopa was significantly reduced from mean values of patients with a sustained response to L-dopa therapy. [99mTc]-HM-PAO caudate and putamen uptake indexes in PD were similar to control values, even in patients with deteriorated therapeutic response. Our results indicate that BG D2 receptor alterations in PD may contribute to the altered response to L-dopa.

    Topics: Adult; Aged; Basal Ganglia; Benzamides; Female; Humans; Levodopa; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Pyrrolidines; Receptors, Dopamine; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1993
Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization.
    European journal of nuclear medicine, 1993, Volume: 20, Issue:4

    Regional cerebral blood flow was assessed in 19 patients with early idiopathic Parkinson's disease (PD) and 12 control subjects of similar age by single-photon emission tomography using technetium-99m hexamethylpropylene amine oxime (HMPAO). Of the patients with PD, seven were mildly demented and 15 presented with hemiparkinsonism. Mean HMPAO cortical or basal ganglia/cerebellum activity ratios were calculated. Mean cortical and regional uptake ratios in non-demented PD patients were not significantly different from values in the controls. In contrast, besides generalized cortical hypoperfusion, demented PD patients had significantly lower HMPAO uptake in the frontal and basal ganglia regions than non-demented patients. These observations support the hypothesis of impaired neuronal activity in both cortical and subcortical regions of the brain in demented PD patients. In hemiparkinsonian patients, the only asymmetrical finding was a relative hypoperfusion in the contralateral parietal region. This may be due to deafferentation of the thalamoparietal pathways. The lack of asymmetrical uptake in basal ganglia in our PD patients may be explained by their staging at the time of the investigation (stage I and II, Hoehn and Yahr scale).

    Topics: Aged; Brain; Dementia; Female; Humans; Male; Organotechnetium Compounds; Oximes; Parkinson Disease; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1993
Cognition and 99Tcm-HMPAO SPECT in Parkinson's disease.
    Nuclear medicine communications, 1992, Volume: 13, Issue:10

    99Tcm-hexamethylpropyleneamine oxime (HMPAO) single photon emission computed tomography (SPECT) of brain was performed in 43 unselected patients with Parkinson's disease to evaluate whether low cerebral perfusion on SPECT correlated with cognitive impairment in the patients. All patients received neurological, Mini-Mental State Examination and a neuropsychological assessment. Eighteen (41.9%) of the 43 patients were demented. Thirty patients (69.8%) had abnormal SPECT: 17 had perfusion defects in cortical regions, eight in basal ganglia and five in both regions. Of the 22 patients with abnormal cortical perfusion, 15 (68.2%) were demented; only three (14.3%) of the 21 patients without cortical defect were demented (P < 0.01). Twelve of the 15 demented patients had low perfusion in the parietal region alone or in parietal and occipital regions. The cortical perfusion defects, present in 22 (51.2%) Parkinson's patients, are highly correlated with cognitive impairment. The pattern of SPECT abnormality in most demented patients with Parkinson's disease is similar to that seen in Alzheimer's disease, suggesting that the underlying pathophysiology for dementia in patients with Parkinson's disease may be similar to that in Alzheimer's disease.

    Topics: Adult; Aged; Cerebrovascular Circulation; Cognition Disorders; Dementia; Female; Humans; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1992
The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:2

    Alzheimer's disease produces regional abnormalities in brain blood flow and metabolism that may result in recognizable scintigraphic patterns. We determined the predictive value of 99mTc-HMPAO SPECT for the presence of Alzheimer's disease based on a prospective study of 132 consecutive patients coming to our nuclear medicine clinical unit for evaluation of their memory loss or cognitive abnormalities. During clinical follow-up averaging 10.1 mo, a final diagnosis was established in 113 patients, 52 of which had Alzheimer's disease. The probability of Alzheimer's disease was determined for seven scintigraphic patterns. The probability was 19% that patients with memory loss and normal perfusion had Alzheimer's disease. For abnormal perfusion patterns, the probability of Alzheimer's disease was 82% with bilateral temporoparietal defects, 77% with bilateral temporoparietal defects with additional defects, 57% with unilateral temporoparietal defects, 43% with frontal defects only, 18% with other large defects and 0% with multiple small cortical defects. We conclude that for 99mTc-HMPAO SPECT the predictive value of bilateral temporoparietal defects for Alzheimer's disease is high, while the perfusion patterns of unilateral temporoparietal perfusion defects and frontal defects only, which occur in 20% of patients with Alzheimer's disease, are not predictive of that disease.

    Topics: AIDS Dementia Complex; Alzheimer Disease; Cerebrovascular Circulation; Dementia, Vascular; Diagnosis, Differential; Humans; Organotechnetium Compounds; Oximes; Parkinson Disease; Predictive Value of Tests; Probability; Prospective Studies; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1992
Evolution of technetium-99m-HMPAO SPECT and brain mapping in a patient presenting with echolalia and palilalia.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1991, Volume: 32, Issue:8

    A 78-yr-old woman presented with transient echolalia and palilalia. She had suffered from Parkinson's disease for 2 yr. Routine laboratory examination showed hypotonic hyponatremia, but was otherwise unremarkable. Brain mapping revealed a bifrontal delta focus, more pronounced on the right. Single photon emission computed tomography (SPECT) of the brain with technetium-99m labeled d,l hexamethylpropylene-amine oxime (99mTc-HMPAO), performed during the acute episode showed relative frontoparietal hypoactivity. Brain mapping performed after disappearance of the echolalia and palilalia, which persisted only for 1 day, was normal. By contrast, SPECT findings persisted for more than 3 wk. Features of particular interest in the presented patient are the extensive defects seen on brain SPECT despite the absence of morphologic lesions, the congruent electrophysiologic changes and their temporal relationship with the clinical evolution.

    Topics: Aged; Brain; Brain Mapping; Echolalia; Female; Frontal Lobe; Humans; Organotechnetium Compounds; Oximes; Parietal Lobe; Parkinson Disease; Technetium Tc 99m Exametazime; Time Factors; Tomography, Emission-Computed, Single-Photon

1991
A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia.
    European journal of nuclear medicine, 1991, Volume: 18, Issue:1

    Regional cerebral perfusion was evaluated by single photon emission computed tomography (SPET) using technetium 99m hexamethylpropylene amine oxime (99mTc-HMPAO) as a tracer, in 13 control subjects and 44 age-matched patients suffering from dementia of the Alzheimer's type (DAT, n = 19), presumed Pick's disease (n = 5), idiopathic Parkinson's disease with dementia (DPD, n = 15) and progressive supranuclear palsy (PSP, n = 5). HMPAO uptake was measured in the superior frontal, inferior frontal, parietal, temporal and occipital cortices, and the perfusion values were expressed as cortical/cerebellar activity ratios. As compared with controls, tracer uptake ratios in the DAT group were significantly reduced over all cortical regions, with the largest defects in the parieto-temporal and superior frontal cortices. A marked hypoperfusion affecting the superior and inferior frontal cortices was found in Pick's disease, whereas a mild but significant hypoperfusion was observed only in the superior frontal cortex of patients with PSP. In the DPD group, HMPAO uptake was significantly reduced in the parietal, temporal and occipital cortices, but not in the frontal cortex. These results show that DAT and DPD share an opposite anteroposterior HMPAO uptake defect as compared with the Pick's and PSP groups.

    Topics: Aged; Alzheimer Disease; Brain; Dementia; Female; Humans; Male; Organotechnetium Compounds; Oximes; Parkinson Disease; Supranuclear Palsy, Progressive; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1991
A new approach to brain imaging.
    Radiography today, 1989, Volume: 55, Issue:622

    Topics: Brain; Brain Diseases; Dementia; Humans; Huntington Disease; Organotechnetium Compounds; Oximes; Parkinson Disease; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1989
Cerebral blood flow measured by SPECT as a diagnostic tool in the study of dementia.
    Psychiatry research, 1989, Volume: 29, Issue:3

    Topics: Alzheimer Disease; Cerebral Cortex; Cerebrovascular Circulation; Dementia; Dementia, Multi-Infarct; Humans; Huntington Disease; Organotechnetium Compounds; Oximes; Parkinson Disease; Regional Blood Flow; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1989
[SPECT findings in the hemiparkinson syndrome using 99mTc-HMPAO].
    Nuklearmedizin. Nuclear medicine, 1989, Volume: 28, Issue:3

    The symptoms of Parkinson's disease often begin on one side of the body and continue to do so as the disease progresses. First SPECT results in 4 patients with hemiparkinsonism using 99mTc-HMPAO as perfusion marker are reported. Three patients exhibited reduced tracer uptake in the contralateral basal ganglia. One patient who was under therapy for 1 year, showed a different perfusion pattern with reduced uptake in both basal ganglia. These results might indicate reduced perfusion secondary to reduced striatal neuronal activity.

    Topics: Basal Ganglia; Female; Functional Laterality; Humans; Male; Middle Aged; Organometallic Compounds; Oximes; Parkinson Disease; Perfusion; Technetium; Technetium Tc 99m Exametazime; Tomography, Emission-Computed

1989
Technetium-99m HMPAO imaging in patients with basal ganglia disease.
    The British journal of radiology, 1988, Volume: 61, Issue:730

    Technetium 99m hexamethylpropylene-amine oxime (HMPAO) is trapped by cerebral grey matter and the basal ganglia on its first pass through the brain. To assess its potential for studying patients with diseases of the basal ganglia, a study of 15 normal volunteers and 32 patients with known or suspected basal ganglia disease have been investigated. Sixteen patients with idiopathic Parkinson's disease showed no abnormality of the basal ganglia and varying degrees of cerebral underperfusion consistent with their intellectual status. Eight patients with Huntington's chorea showed a characteristic pattern of reduced or absent caudate nucleus uptake. Patients with diseases affecting the basal ganglia, such as Fahr's disease, Wilson's disease and hemibalismus had varying degrees of basal ganglia underperfusion as demonstrated by an HMPAO scan. We believe that this new radiopharmaceutical for the demonstration of cerebral blood flow shows significant potential for the diagnosis and management of patients with basal ganglia disease.

    Topics: Adult; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cerebral Hemorrhage; Hepatolenticular Degeneration; Humans; Huntington Disease; Middle Aged; Organometallic Compounds; Oximes; Parkinson Disease; Technetium; Technetium Tc 99m Exametazime; Thalamic Diseases; Tomography, Emission-Computed; Tomography, X-Ray Computed

1988
The use of technetium-99m-HM-PAO in the assessment of patients with dementia and other neuropsychiatric conditions.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 1988, Volume: 8, Issue:6

    One hundred fourteen patients suffering from neuropsychiatric conditions have been studied using 99mTc-labeled hexamethylpropyleneamine oxime (HM-PAO) and single photon emission computed tomography (SPECT). Ninety-one patients had a firm clinical diagnosis while 23 were examined without knowledge of the clinical diagnosis. Of the 91 patients, 51 were suffering from dementia, 25 multi-infarct type and 26 Alzheimer's disease. In 19 of the Alzheimer's patients, a characteristic pattern of decreased perfusion in the parieto-occipital regions was demonstrated while those with multi-infarct type showed varying degrees of irregular uptake in the cerebral cortex. These appearances are similar to those shown with positron emission tomography (PET) and we believe that HM-PAO will provide a widely available method for identifying patients with Alzheimer's disease. Twenty-nine patients were suffering from diseases involving the basal ganglia. Fifteen patients with Parkinson's disease showed no significant abnormality in basal ganglia uptake, while 7 or 8 patients with Huntington's disease who had full examinations showed decreased uptake in the caudate nuclei. Similarly, four of six patients with other basal ganglia diseases showed impaired uptake by basal ganglia, and it is concluded that HM-PAO may be useful for the diagnosis and management of this type of patient. Twenty-three patients received HM-PAO imaging as part of their diagnostic work-up; in 19 of them, detailed follow-up was obtained, which indicated that in 7 cases the result of the HM-PAO scan altered the clinical diagnosis and in 9 cases resulted in a change in management. In the remaining 13 cases, the study was found to be helpful in confirming the diagnosis.

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Basal Ganglia Diseases; Brain; Dementia; Female; Humans; Huntington Disease; Male; Middle Aged; Organometallic Compounds; Oximes; Parkinson Disease; Radionuclide Imaging; Technetium; Technetium Tc 99m Exametazime

1988
[99mTc]-HM-PAO SPECT in Parkinson's disease.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 1988, Volume: 8, Issue:6

    Thirty-six patients affected by Parkinson's disease were studied using single photon emission computed tomography (SPECT) and [99mTc]-HM-PAO as a tracer. The scanning procedure was performed 16-24 h after discontinuation of specific therapy. Tracer activity ratios were determined in 10 pairs of cerebellar, cortical, and subcortical regions. Data were compared with those of 10 age-matched controls. Most of the regions examined did not show any relevant change between parkinsonian and control subjects. Notably, mean activity in striatal regions were similar in the two groups. Increased activity in caudate-putamen was found in patients who were on chronic DOPA therapy. Side-to-side asymmetries in the basal ganglia increased with the severity of the disease. Significant reductions of tracer uptake, from control values, were observed bilaterally in the parietal cortex. These deficits were more pronounced in patients with mental deterioration and in subjects who had been chronically treated with anticholinergic drugs. Parietal perfusion deficits in parkinsonian patients resemble those described in Alzheimer's dementia. These findings suggest that the heterogeneous alterations of regional cerebral blood flow (rCBF) in parkinsonian patients reflect the multifactorial pathophysiology of the disease.

    Topics: Adult; Aged; Brain; Cerebrovascular Circulation; Female; Humans; Male; Middle Aged; Organometallic Compounds; Oximes; Parkinson Disease; Technetium; Technetium Tc 99m Exametazime; Tomography, Emission-Computed

1988
CBF tomograms with [99mTc-HM-PAO in patients with dementia (Alzheimer type and HIV) and Parkinson's disease--initial results.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 1988, Volume: 8, Issue:6

    We present preliminary data on the utility of functional brain imaging with [99mTc]-d,l-HM-PAO and single photon emission computed tomography (SPECT) in the study of patients with dementia of the Alzheimer type (DAT), HIV-related dementia syndrome, and the "on-off" syndrome of Parkinson's disease. In comparison with a group of age-matched controls, the DAT patients revealed distinctive bilateral temporal and posterior parietal deficits, which correlate with detailed psychometric evaluation. Patients with amnesia as the main symptom (group A) showed bilateral mesial temporal lobe perfusion deficits (p less than 0.02). More severely affected patients (group B) with significant apraxia, aphasia, or agnosia exhibited patterns compatible with bilateral reduced perfusion in the posterior parietal cortex, as well as reduced perfusion to both temporal lobes, different from the patients of the control group (p less than 0.05). SPECT studies of HIV patients with no evidence of intracraneal space occupying pathology showed marked perfusion deficits. Patients with Parkinson's disease and the "on-off" syndrome studied during an "on" phase (under levodopa therapy) and on another occasion after withdrawal of levodopa ("off") demonstrated a significant change in the uptake of [99mTc]-d,l-HM-PAO in the caudate nucleus (lower on "off") and thalamus (higher on "off"). These findings justify the present interest in the functional evaluation of the brain of patients with dementia. [99mTc]-d,l-HM-PAO and regional cerebral blood flow (rCBF)/SPECT appear useful and highlight individual disorders of flow in a variety of neuropsychiatric conditions.

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Dementia; Female; Humans; Male; Middle Aged; Organometallic Compounds; Oximes; Parkinson Disease; Technetium; Technetium Tc 99m Exametazime; Tomography, Emission-Computed

1988